GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000028011 | Thyroid | ATC | nuclear division | 207/6293 | 439/18723 | 1.98e-09 | 4.80e-08 | 207 |
GO:000708811 | Thyroid | ATC | regulation of mitotic nuclear division | 67/6293 | 110/18723 | 3.98e-09 | 9.08e-08 | 67 |
GO:000183722 | Thyroid | ATC | epithelial to mesenchymal transition | 87/6293 | 157/18723 | 1.50e-08 | 3.06e-07 | 87 |
GO:001076927 | Thyroid | ATC | regulation of cell morphogenesis involved in differentiation | 59/6293 | 96/18723 | 2.08e-08 | 4.05e-07 | 59 |
GO:001072022 | Thyroid | ATC | positive regulation of cell development | 146/6293 | 298/18723 | 2.36e-08 | 4.56e-07 | 146 |
GO:0000910110 | Thyroid | ATC | cytokinesis | 93/6293 | 173/18723 | 3.59e-08 | 6.67e-07 | 93 |
GO:005178311 | Thyroid | ATC | regulation of nuclear division | 77/6293 | 139/18723 | 1.01e-07 | 1.70e-06 | 77 |
GO:006145827 | Thyroid | ATC | reproductive system development | 193/6293 | 427/18723 | 3.32e-07 | 4.92e-06 | 193 |
GO:005076922 | Thyroid | ATC | positive regulation of neurogenesis | 112/6293 | 225/18723 | 3.53e-07 | 5.21e-06 | 112 |
GO:005076723 | Thyroid | ATC | regulation of neurogenesis | 168/6293 | 364/18723 | 3.73e-07 | 5.48e-06 | 168 |
GO:0016358110 | Thyroid | ATC | dendrite development | 119/6293 | 243/18723 | 4.65e-07 | 6.75e-06 | 119 |
GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
GO:004860825 | Thyroid | ATC | reproductive structure development | 190/6293 | 424/18723 | 8.40e-07 | 1.11e-05 | 190 |
GO:006164017 | Thyroid | ATC | cytoskeleton-dependent cytokinesis | 57/6293 | 100/18723 | 1.29e-06 | 1.65e-05 | 57 |
GO:006048521 | Thyroid | ATC | mesenchyme development | 136/6293 | 291/18723 | 2.04e-06 | 2.43e-05 | 136 |
GO:005196014 | Thyroid | ATC | regulation of nervous system development | 195/6293 | 443/18723 | 2.62e-06 | 3.06e-05 | 195 |
GO:001077023 | Thyroid | ATC | positive regulation of cell morphogenesis involved in differentiation | 46/6293 | 79/18723 | 6.09e-06 | 6.38e-05 | 46 |
GO:005196221 | Thyroid | ATC | positive regulation of nervous system development | 126/6293 | 272/18723 | 8.17e-06 | 8.27e-05 | 126 |
GO:000703015 | Thyroid | ATC | Golgi organization | 79/6293 | 157/18723 | 1.07e-05 | 1.05e-04 | 79 |
GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CUL7 | SNV | Missense_Mutation | rs759549960 | c.1402C>T | p.Arg468Trp | p.R468W | Q14999 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
CUL7 | SNV | Missense_Mutation | | c.2122N>A | p.Leu708Met | p.L708M | Q14999 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CUL7 | SNV | Missense_Mutation | novel | c.4943G>A | p.Arg1648Gln | p.R1648Q | Q14999 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
CUL7 | SNV | Missense_Mutation | | c.1729G>C | p.Glu577Gln | p.E577Q | Q14999 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CUL7 | SNV | Missense_Mutation | novel | c.5326C>A | p.Gln1776Lys | p.Q1776K | Q14999 | protein_coding | deleterious_low_confidence(0.04) | benign(0.059) | TCGA-AC-A3HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CUL7 | SNV | Missense_Mutation | | c.5294N>A | p.Arg1765Gln | p.R1765Q | Q14999 | protein_coding | deleterious_low_confidence(0.04) | benign(0.219) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CUL7 | SNV | Missense_Mutation | novel | c.2117N>T | p.Gln706Leu | p.Q706L | Q14999 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
CUL7 | SNV | Missense_Mutation | novel | c.5264T>C | p.Leu1755Pro | p.L1755P | Q14999 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.808) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CUL7 | SNV | Missense_Mutation | | c.1339N>C | p.Phe447Leu | p.F447L | Q14999 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
CUL7 | SNV | Missense_Mutation | rs776538724 | c.523C>T | p.Arg175Trp | p.R175W | Q14999 | protein_coding | tolerated(0.06) | benign(0.378) | TCGA-E9-A226-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |